FGFR4

By Type:	Pan (28) Selective (11)

Cat. No.	Product Name	Effect	Purity

HY-10981

Lenvatinib	Inhibitor	99.84%
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

HY-18708

Erdafitinib	Inhibitor	99.66%
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

HY-13311

Infigratinib	Inhibitor	99.72%
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-109099

Pemigatinib	Inhibitor	99.73%
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

HY-100818

Futibatinib	Inhibitor	99.65%
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM).

HY-100491

H3B-6527	Inhibitor	≥98.0%
H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC₅₀ of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC₅₀s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity.

HY-160621

CXF-009	Inhibitor
CXF-009 is a selective and covalent FGFR4 inhibitor, with the IC₅₀ of 48 nM. CXF-009 targeting Cys477 and Cys552 of FGFR4, and can be used for the study of hepatocellular carcinoma.

HY-161326

CXF-007	Inhibitor
CXF-007 is a potent and specific FGFR4 inhibitor with a IC₅₀ value of 7 nM. CXF-007 has antitumor activity.

HY-13330

Fexagratinib	Inhibitor	99.85%
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-10981A

Lenvatinib mesylate	Inhibitor	99.86%
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

HY-100492

Fisogatinib	Inhibitor	99.87%
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling.

HY-101568

Roblitinib	Inhibitor	99.74%
Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC₅₀ of 1.9 nM. Roblitinib has antitumor activity.

HY-12823

BLU9931	Inhibitor	99.95%
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.

HY-13304

LY2874455	Inhibitor	98.03%
LY2874455 is a pan-FGFR inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

HY-100019

Rogaratinib	Inhibitor	99.86%
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/Flt-4/FLT4), 201 nM (FGFR4), respectively.

HY-119367

ODM-203	Inhibitor	99.91%
ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC₅₀ values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/Flt-4/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment.

HY-19957

Zoligratinib	Inhibitor	99.76%
Zoligratinib (Debio 1347) is an orally available and selective FGFR inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-19983

ASP5878	Inhibitor	99.86%
ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC₅₀ values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.

HY-15599

SSR128129E	Inhibitor	99.85%
SSR128129E is an orally available and allosteric FGFR inhibitor with an IC₅₀ of 1.9 μM for FGFR1.

HY-13311A

Infigratinib phosphate	Inhibitor	99.74%
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.

FGFR4 Related Products (39)